• Subscribe
  • Log In
  • Home
  • Daily Diary
  • Asset Class
    • U.S. Equity
    • Fixed Income
    • Global Equity
    • Commodities
    • Currencies
  • Sector
    • Basic Materials
    • Consumer Discretionary
    • Consumer Staples
    • Energy
    • Financial Services
    • Healthcare
    • Industrials
    • Real Estate
    • Technology
    • Telecom Services
    • Transportation
    • Utilities
  • Latest
    • Articles
    • Video
    • Columnist Conversations
    • Best Ideas
    • Stock of the Day
  • Street Notes
  • Authors
    • Bruce Kamich
    • Doug Kass
    • Jim "Rev Shark" DePorre
    • Helene Meisler
    • Jonathan Heller
    • - See All -
  • Options
  • RMPIA
  • Switch Product
    • Action Alerts PLUS
    • Quant Ratings
    • Real Money
    • Real Money Pro
    • Retirement
    • Stocks Under $10
    • TheStreet
    • Top Stocks
    • TheStreet Smarts
  1. Home
  2. / Investing
  3. / Healthcare

Big Pharma Has No Rx for Viral Social Media Reactions

Immediate public backlash on social media could end up being a more costly verdict for drugmakers' pricing powers.
By JAMES PASSERI Aug 30, 2016 | 09:30 AM EDT
Stocks quotes in this article: MYL, VRX, FB, TWTR, AZN, NVO, MNK

Since the advent of Facebook  (FB)  and Twitter (TWTR) , a losing verdict in the court of public opinion isn't just swift, it's instantaneous.

Social media has played a greater role by guiding Big Pharma watchdogs -- who have been on the prowl in hopes of shining a light on companies that have hiked drug prices by hundreds of percent -- toward companies that have provoked the public outrage of patients and family members.

Just look at Mylan's (MYL) recent EpiPen fiasco.

After catching the public ire's last week for raising prices on the popular allergy treatment (by roughly 480% to about $600 over the past eight years) Mylan said Monday that it will be rolling out a generic version of EpiPen at a roughly 50% discount from last week's prices. Mylan's CEO Heather Bresch also noted that the move was a reaction to "deep frustration" among the public surrounding EpiPen pricing.

The regulatory scrutiny in Washington began to mount this year when the U.S. Senate Special Committee on Aging said in March it was looking inside the "monopoly business model" that has produced "sudden price spikes" among decades-old drugs. Shortly afterward, the panel said it was poring through about 400,000 pages of documents subpoenaed by Turing and Retrophin -- a hedge fund and a biotech company formerly run by Martin Shkreli, who became notorious last year for jacking up the price of HIV-treatment Daraprim.

The panel was then quick to turn its sites on Valeant Pharmaceuticals (VRX) , the beleaguered Canadian drugmaker that's amassed about $31 billion in debt through years of credit-fueled acquisitions of companies and drugs whose prices were subsequently lifted to controversial levels. (Ousted Valeant CEO Michael Pearson, who was replaced by Joseph Papa this spring, apologized to the committee this April for putting Valeant shareholders ahead of patients.)

With political pressure mounting -- especially from the campaign of Democratic presidential nominee Hillary Clinton, who lambasted drugmakers for "price gouging" and "predatory" business models -- investors began to ask, "Who's next?"

And then the very same Senate panel, the Subcommittee on Aging, said Wednesday that it was seeking answers about Mylan's "drastic price increase" on its allergy treatment.

Those who follow social media (especially trending Twitter and Facebook news feeds) noticed when Brooklyn actress Mellini Kantayya uploaded a Petition2Congress.com link to "Stop the EpiPen Price Gouging" to her 800-some friends on Facebook, according to a Thursday New York Times report. It didn't take long for the petition to net more than 80,000 signatures, produce some fiery rhetoric from the Clinton campaign, and send Mylan running.

Grandchild w severe allergies needs life saving #Epipen. Cost has soared. Luckily we can pay the $600. Impossible for many scared parents

— mia farrow (@MiaFarrow) August 23, 2016

When Martin Shkreli Calls A Pharma Company Out, You Know It Screwed Up #epipen https://t.co/LAJ8gNucna

— Leo (@4eo) August 20, 2016

In 2007, an #EpiPen cost $57.
Today: $600. All for about $1 worth of injectable medicine https://t.co/MssBCkTH1H #Mylan

— Roben Farzad (@robenfarzad) August 23, 2016

The lesson for investors is that some pharmaceutical companies may be more social-media-proof than others. Take Mallinckrodt's (MNK) Acthar Gel, which short-seller Andrew Left told Real Money is the lifeblood of the Irish drugmaker. "The company lives and breathes on Acthar," he said in a phone interview last week, noting that the multiple-sclerosis treatment is now listed at about $34,000 a vial from list prices of about $50 in the early 1990s.

While Left said that Mallinckrodt will undoubtedly be called to Capitol Hill, it has not received the same social-media scrutiny as Mylan's EpiPen. That may be because Mallinckrodt's drug doesn't have the wide reach that EpiPen has -- think of all those kids with peanut allergies.

Aside from Facebook and Twitter feeds -- which may prove to be the Achilles' heel to orphan drugs that have thus far slipped under the radar of watchdogs -- investors can easily track petitions that are beginning to gain momentum, as "Stop the EpiPen Price Gouging" has. 

The most recent example is a plea for Congress to curb the costs of insulin, which is often packaged as a simple injectable device similar to EpiPen. Some of the primary producers of insulin devices used by diabetics include Novo Nordisk  (NVO) , MannKind MNKD and AstraZeneca (AZN) .

#Pharma #PriceGouging should be a crime. Whether #Insulin #MS drugs #HIV #Hepatitis or #Cancer @chrissyfarr @MMaxwellStroud @missoulian

— Al Colvin (@algcolvin) August 29, 2016

Patients with #diabetes struggle to afford #insulin -- https://t.co/LFGbaVMyRM #T1D

— Faustman Lab (@FaustmanLab) August 29, 2016

"Insulin costs, like Mylan's EpiPens, have increased by over 400% in recent years," according to the the petition, which has triggered readers to send more than 20,000 letters to Congress as of Monday. "Americans pay the highest prices for insulin in the world," it continues. "People are unable to afford these prices, and are being forced to make difficult choices."

Today, drugmakers no longer have just regulators to worry about in protecting their pricing powers. And shareholders are beginning to learn the immediate public backlash on Twitter and Facebook is becoming a faster -- and more costly -- verdict.

Get an email alert each time I write an article for Real Money. Click the "+Follow" next to my byline to this article.

Employees of TheStreet are restricted from owning individual securities.

Action Alerts PLUS, which Jim Cramer co-manages as a charitable trust, is long FB.

TAGS: Investing | U.S. Equity | Regulation | Markets | Healthcare | Drug Approvals | Stocks | Agriculture

More from Healthcare

Bearish Bets: 3 Stocks You Should Really Consider Shorting This Week

Bob Lang
May 28, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

These Small-Cap Biotech Stocks Have the Wind at Their Back

Bret Jensen
May 24, 2023 1:30 PM EDT

After getting a 'win' earlier this week on an acquisition, let's highlight a few similar names in my portfolio.

Why Are CRISPR Therapeutics Charts Saying 'Buy'?

Bruce Kamich
May 15, 2023 1:00 PM EDT

Here's where traders could go long.

Is It Time to Get Back Into CVS Health? Here's a Trade Idea

Stephen Guilfoyle
May 15, 2023 10:30 AM EDT

The fundamentals are not in tip-top shape, and now investors have reduced guidance to deal with.

Bearish Bets: 3 Well-Known Stocks You Should Consider Shorting This Week

Bob Lang
May 14, 2023 10:30 AM EDT

These recently downgraded names are displaying both quantitative and technical deterioration.

Real Money's message boards are strictly for the open exchange of investment ideas among registered users. Any discussions or subjects off that topic or that do not promote this goal will be removed at the discretion of the site's moderators. Abusive, insensitive or threatening comments will not be tolerated and will be deleted. Thank you for your cooperation. If you have questions, please contact us here.

Email

CANCEL
SUBMIT

Email sent

Thank you, your email to has been sent successfully.

DONE

Oops!

We're sorry. There was a problem trying to send your email to .
Please contact customer support to let us know.

DONE

Please Join or Log In to Email Our Authors.

Email Real Money's Wall Street Pros for further analysis and insight

Already a Subscriber? Login

Columnist Conversation

  • 09:48 AM EDT CHRIS VERSACE

    Latest AAP Podcast With Portillo's CEO!

    Listen in as we talk with a rising star in the Chi...
  • 03:25 PM EDT JAMES "REV SHARK" DEPORRE

    This Weekend on Real Money

    Don't Just Sit There and 'Hope' for Your Stocks, M...
  • 07:32 AM EDT BOB LANG

    Webinar Thursday After the Close: Option Spread Trading

    Thursday, my good friend and colleague Sam DeMarco...
  • See More

COLUMNIST TWEETS

  • A Twitter List by realmoney
About Privacy Terms of Use

© 1996-2023 TheStreet, Inc., 225 Liberty Street, 27th Floor, New York, NY 10281

Need Help? Contact Customer Service

Except as otherwise indicated, quotes are delayed. Quotes delayed at least 20 minutes for all exchanges. Market Data & Company fundamental data provided by FactSet. Earnings and ratings provided by Zacks. Mutual fund data provided by Valueline. ETF data provided by Lipper. Powered and implemented by FactSet Digital Solutions Group.

TheStreet Ratings updates stock ratings daily. However, if no rating change occurs, the data on this page does not update. The data does update after 90 days if no rating change occurs within that time period.

FactSet calculates the Market Cap for the basic symbol to include common shares only. Year-to-date mutual fund returns are calculated on a monthly basis by Value Line and posted mid-month.

Compare Brokers

Please Join or Log In to manage and receive alerts.

Follow Real Money's Wall Street Pros to receive real-time investing alerts

Already a Subscriber? Login